Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...

After more than a decade in charge of the most influential organization representing the U.S. pharmaceutical industry, the ...

Japan’s Shionogi is joining the spate of drugmakers to announce manufacturing commitments in the U.S. since last year, albeit ...

Johnson & Johnson’s immunology drug Tremfya is looking to challenge AbbVie’s dominance in 2026, securing the top spot as the ...

Pfizer is making more changes to its layout in California by stepping away from a South San Francisco office site that used ...

With another year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit ...

Cognito Therapeutics is partnering with a nonprofit to “Change the D-Word,” aiming to eliminate the use of “dementia,” a ...

For the second time in a span of four months, Insmed’s Brinsupri has come up short in a mid-stage trial designed to expand ...

U.S. Olympic gold medal-winning athlete Lindsey Vonn is once again teaming up with infectious disease biopharma Invivyd for a ...

One year into his tumultuous tenure as the FDA’s commissioner, Marty Makary, M.D., has laid out ambitious internal goals and ...

The plummeting demand for Merck & Co.’s HPV vaccine Gardasil in China has forced the New Jersey drugmaker to rework its ...

Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. | ...